黄山胶囊(002817) - 2018 Q1 - 季度财报

Financial Performance - Revenue for Q1 2018 was CNY 75,303,393.11, a decrease of 1.81% compared to CNY 76,688,972.57 in the same period last year[7] - Net profit attributable to shareholders was CNY 10,661,608.63, down 18.66% from CNY 13,107,226.43 year-on-year[7] - Net profit excluding non-recurring gains and losses was CNY 7,515,475.62, a decline of 28.70% compared to CNY 10,540,413.02 in the previous year[7] - The net profit attributable to shareholders for the first half of 2018 is expected to range from 1,781.37 million to 3,014.63 million RMB, representing a decrease of 35.00% to an increase of 10.00% compared to the same period in 2017[20] - The net profit for the first half of 2017 was 2,740.57 million RMB, indicating a significant year-over-year change[20] - Net profit for the quarter was CNY 10,318,001.69, down from CNY 13,107,226.43 in the same period last year, reflecting a decrease of approximately 21.4%[38][41] - Earnings per share (EPS) for the quarter was CNY 0.12, compared to CNY 0.15 in the previous period, showing a decline of 20%[38][41] Cash Flow and Assets - Operating cash flow net amount increased by 121.11% to CNY 1,767,071.09 from a negative CNY 8,371,038.19 in the same period last year[7] - Cash flow from operating activities generated a net cash inflow of CNY 1,767,071.09 for the quarter[42] - The net cash flow from operating activities for the first quarter was 3,712,233.24 CNY, a significant improvement compared to a net outflow of -8,371,038.19 CNY in the same period last year[47] - Total cash inflow from investment activities was 30,325,356.16 CNY, while cash outflow amounted to 120,546,477.92 CNY, resulting in a net cash flow of -90,221,121.76 CNY[47] - The company reported a net decrease in cash and cash equivalents of -86,554,181.61 CNY for the quarter, with an ending balance of 61,004,606.45 CNY[48] - The cash and cash equivalents at the beginning of the period were 147,558,788.06 CNY, down from 157,518,618.98 CNY in the previous year[48] Assets and Liabilities - Total assets at the end of the reporting period were CNY 762,611,052.72, an increase of 3.23% from CNY 738,732,768.23 at the end of the previous year[7] - The total liabilities increased to CNY 83,809,704.33 from CNY 72,629,202.85, marking an increase of approximately 15.5%[37] - The total equity of the company rose to CNY 677,084,852.88 from CNY 666,103,565.38, an increase of about 1.7%[37] Operational Costs and Expenses - Total operating costs amounted to CNY 64,744,672.16, with operating costs specifically at CNY 49,740,868.79, indicating an increase from CNY 47,489,362.83 in the previous period[36][40] - Sales expenses were reported at CNY 8,279,737.86, up from CNY 7,311,213.59 in the previous period, indicating an increase of approximately 13.3%[37][40] - The company reported investment income of CNY 806,371.15, a decrease from CNY 1,777,891.38 in the previous period, reflecting a decline of about 54.7%[40][41] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 15,460, with the top ten shareholders holding a combined 51.69% of shares[11] Performance Challenges - The decline in performance is attributed to increased depreciation and related costs from the Huangjiayuan New District project, rising raw material prices due to environmental policies, and intensified market competition in the pharmaceutical industry[20] Receivables and Prepayments - Accounts receivable increased by CNY 19,425,900, a growth of 34.48%, mainly due to delayed collection of receivables[15] - Prepayments increased by CNY 993,900, a significant increase of 415.09%, primarily due to higher advance payments for materials[15]